Teva Pharmaceuticals (TEVA) recovered in the last month as biotech stocks found buyers. For July, the selling pressure from technology, led by Apple's steady fall and Tesla's big correction - thank Goldman Sachs - could hurt TEVA stock. $TEVA, Teva Pharmaceutical Industries Limited / H1 Still, Teva has strong upside and new leadership that will consolidate the generics unit.TEVA will not fall below $30.Agree or disagree?Login to vote! Sign in via Stocktwits."Like" this post.Related: ENDP is deep value. VRX is treading towards the $19 - $20 PT (price target). Allergan (AGN) shed its generics unit.